Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)- methyl]-phenoxy}-pentane (AMG-126737)

Clifford D. Wright, Andrew M. Havill, Scot C. Middleton, Mohammed A. Kashem, David J. Dripps, William M. Abraham, David S. Thomson, Laurence E. Burgess

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Emerging evidence suggests that mast cell tryptase is a therapeutic target for the treatment of asthma. The effects of this serine protease are associated with both pathophysiologic pulmonary responses and pathologic changes of the asthmatic airway. In this study, the tryptase inhibitor 1,5- bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy}-pentane (AMG-126737) was evaluated for its pharmacologic effects against allergen- induced airway responses. AMG-126737 is a potent inhibitor of human lung mast cell tryptase (K(i) = 90 nM), with greater than 10- to 200-fold selectivity versus other serine proteases. Intratracheal administration of AMG-126737 inhibited the development of airway hyperresponsiveness in allergen- challenged guinea pigs with an ED50 of 0.015 mg/kg. In addition, the compound exhibited oral activity in the guinea pig model. The in vivo activity of AMG-126737 was confirmed in a sheep model of allergen-induced airway responses, where the compound inhibited early and late phase bronchoconstriction responses and the development of airway hyperresponsiveness. These results support the proposed role of tryptase in the pathology of asthma and suggest that AMG-126737 has potential therapeutic utility in this pulmonary disorder.

Original languageEnglish
Pages (from-to)1989-1996
Number of pages8
JournalBiochemical Pharmacology
Volume58
Issue number12
DOIs
StatePublished - Dec 15 1999
Externally publishedYes

Fingerprint

Tryptases
Allergens
Lung
Serine Proteases
Guinea Pigs
Asthma
Bronchoconstriction
Pathology
1,5-bis-(4-((3-carbamimidoyl-benzenesulfonylamino)-methyl)-phenoxy)-pentane
Sheep
Therapeutics

Keywords

  • AMG-126737
  • Asthma
  • Inhibition
  • Pulmonary responses
  • Tryptase

ASJC Scopus subject areas

  • Pharmacology

Cite this

Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)- methyl]-phenoxy}-pentane (AMG-126737). / Wright, Clifford D.; Havill, Andrew M.; Middleton, Scot C.; Kashem, Mohammed A.; Dripps, David J.; Abraham, William M.; Thomson, David S.; Burgess, Laurence E.

In: Biochemical Pharmacology, Vol. 58, No. 12, 15.12.1999, p. 1989-1996.

Research output: Contribution to journalArticle

Wright, Clifford D. ; Havill, Andrew M. ; Middleton, Scot C. ; Kashem, Mohammed A. ; Dripps, David J. ; Abraham, William M. ; Thomson, David S. ; Burgess, Laurence E. / Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)- methyl]-phenoxy}-pentane (AMG-126737). In: Biochemical Pharmacology. 1999 ; Vol. 58, No. 12. pp. 1989-1996.
@article{1ba0fc4a0f18467eb46e563e5316ce00,
title = "Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)- methyl]-phenoxy}-pentane (AMG-126737)",
abstract = "Emerging evidence suggests that mast cell tryptase is a therapeutic target for the treatment of asthma. The effects of this serine protease are associated with both pathophysiologic pulmonary responses and pathologic changes of the asthmatic airway. In this study, the tryptase inhibitor 1,5- bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy}-pentane (AMG-126737) was evaluated for its pharmacologic effects against allergen- induced airway responses. AMG-126737 is a potent inhibitor of human lung mast cell tryptase (K(i) = 90 nM), with greater than 10- to 200-fold selectivity versus other serine proteases. Intratracheal administration of AMG-126737 inhibited the development of airway hyperresponsiveness in allergen- challenged guinea pigs with an ED50 of 0.015 mg/kg. In addition, the compound exhibited oral activity in the guinea pig model. The in vivo activity of AMG-126737 was confirmed in a sheep model of allergen-induced airway responses, where the compound inhibited early and late phase bronchoconstriction responses and the development of airway hyperresponsiveness. These results support the proposed role of tryptase in the pathology of asthma and suggest that AMG-126737 has potential therapeutic utility in this pulmonary disorder.",
keywords = "AMG-126737, Asthma, Inhibition, Pulmonary responses, Tryptase",
author = "Wright, {Clifford D.} and Havill, {Andrew M.} and Middleton, {Scot C.} and Kashem, {Mohammed A.} and Dripps, {David J.} and Abraham, {William M.} and Thomson, {David S.} and Burgess, {Laurence E.}",
year = "1999",
month = "12",
day = "15",
doi = "10.1016/S0006-2952(99)00304-4",
language = "English",
volume = "58",
pages = "1989--1996",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)- methyl]-phenoxy}-pentane (AMG-126737)

AU - Wright, Clifford D.

AU - Havill, Andrew M.

AU - Middleton, Scot C.

AU - Kashem, Mohammed A.

AU - Dripps, David J.

AU - Abraham, William M.

AU - Thomson, David S.

AU - Burgess, Laurence E.

PY - 1999/12/15

Y1 - 1999/12/15

N2 - Emerging evidence suggests that mast cell tryptase is a therapeutic target for the treatment of asthma. The effects of this serine protease are associated with both pathophysiologic pulmonary responses and pathologic changes of the asthmatic airway. In this study, the tryptase inhibitor 1,5- bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy}-pentane (AMG-126737) was evaluated for its pharmacologic effects against allergen- induced airway responses. AMG-126737 is a potent inhibitor of human lung mast cell tryptase (K(i) = 90 nM), with greater than 10- to 200-fold selectivity versus other serine proteases. Intratracheal administration of AMG-126737 inhibited the development of airway hyperresponsiveness in allergen- challenged guinea pigs with an ED50 of 0.015 mg/kg. In addition, the compound exhibited oral activity in the guinea pig model. The in vivo activity of AMG-126737 was confirmed in a sheep model of allergen-induced airway responses, where the compound inhibited early and late phase bronchoconstriction responses and the development of airway hyperresponsiveness. These results support the proposed role of tryptase in the pathology of asthma and suggest that AMG-126737 has potential therapeutic utility in this pulmonary disorder.

AB - Emerging evidence suggests that mast cell tryptase is a therapeutic target for the treatment of asthma. The effects of this serine protease are associated with both pathophysiologic pulmonary responses and pathologic changes of the asthmatic airway. In this study, the tryptase inhibitor 1,5- bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy}-pentane (AMG-126737) was evaluated for its pharmacologic effects against allergen- induced airway responses. AMG-126737 is a potent inhibitor of human lung mast cell tryptase (K(i) = 90 nM), with greater than 10- to 200-fold selectivity versus other serine proteases. Intratracheal administration of AMG-126737 inhibited the development of airway hyperresponsiveness in allergen- challenged guinea pigs with an ED50 of 0.015 mg/kg. In addition, the compound exhibited oral activity in the guinea pig model. The in vivo activity of AMG-126737 was confirmed in a sheep model of allergen-induced airway responses, where the compound inhibited early and late phase bronchoconstriction responses and the development of airway hyperresponsiveness. These results support the proposed role of tryptase in the pathology of asthma and suggest that AMG-126737 has potential therapeutic utility in this pulmonary disorder.

KW - AMG-126737

KW - Asthma

KW - Inhibition

KW - Pulmonary responses

KW - Tryptase

UR - http://www.scopus.com/inward/record.url?scp=0032742390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032742390&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(99)00304-4

DO - 10.1016/S0006-2952(99)00304-4

M3 - Article

C2 - 10591155

AN - SCOPUS:0032742390

VL - 58

SP - 1989

EP - 1996

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 12

ER -